TLC HealthCare™ Wound Specialists, in conjunction with the Wound Care Center at Northwest Hospital, utilizes the most current best practices for effective wound treatment. Clinicians focus on pressure ulcers, vascular ulcers and diabetic wounds, along with chronic or palliative, non-healing wounds. The individual needs and goals of each patient are considered in determining the course of treatment.
The TLC HealthCare™ Wound Specialists provide education to patients, staff and family members regarding preventative measures and the expectations for healing, especially for patients with multiple co-morbid diagnoses. Wound care education is provided to our affiliates in the community as requested.
To request more information about the TLC HealthCare™ Wound Specialist services please call (520) 299-3968 or you may contact the Wound Care Center at Northwest Hospital 6130 N La Cholla Blvd Suite 111 Tucson, AZ 85741 (520) 469-8168.
We are pleased to announce that Northwest Hospital has supported our efforts to bring new technologies into the center in addition to hyperbaric medicine.
First, we have added ultrasound debridement to our modalities available to the care of the wounds. Our patients are eager to request this technology as the level of pain is considerably much less than sharp debridement. Additional benefits include faster debridements, ability to reach difficult locations and bioburden reduction in the wound bed. We have partnered with the Misonix Corporation with the use of the SonicOne® device. We are the first center in Southern Arizona to have this important technology in our armamentarium.
Second, we now have available Total Contact Casting, the gold standard for the care of the diabetic foot ulcer. This offers the eligible patient the best opportunity for off-loading in order to heal the diabetic ulcer. We are using technology called TCC-EZ® developed by the MedEfficiency Corporation.
Third, we are able to assess our patients with lower extremity wounds for vascular screening directly in the center by testing skin perfusion pressures and pulse volume recordings. This allows us to determine if we can compress the lower extremities safely and/or whether the patient requires further vascular assessments with specialists. The technology we utilize is the Sensilase® recorder by the Vasamed Corporation.
Fourth, we have expanded the use of the hyperbaric technology to a wide array of disease states that have included diabetic ulcers, osteomyelitis, radiation injuries, failed grafts, and radionecrosis of the jaw.
Fifth, we have expanded our use of growth factor technology with the use of two novel products that include Oasis®, which is freeze-dried pig intestine; and Apligraf®, live, laboratory grown tissue. With the appropriate wound, we are able to expose the wound to the important growth factor and matrix that enhance and propel wound healing for our patients.
